Investing News Biogen Decides to Halt Aduhelm, Shifting Focus to Alternative Alzheimer’s Treatments January 31, 2024
Investing News Biogen Reduces Profit Forecast Due to Alzheimer’s Drug Launch Costs and M&A, Shares Decline November 8, 2023
Investing News Biogen Stock Fell Because It Thinks a New Alzheimer’s Drug Will Hurt Its 2023 Outlook February 15, 2023
Investing News Analysts Believe That Biogen Stock Fell Due to the Rapid Approval of Lecanemab January 5, 2023
Investing News Goldman Sachs Upgraded Biogen Stock to Buy Due to Improved Alzheimer’s Disease Prospects October 26, 2022